(AOF) – Thibaut du Fayet, Deputy CEO of Pherecydes Pharma since March 2022, has been appointed CEO. This is what the company announced at the end of its mixed general meeting, which voted to separate the functions of general manager and chairman of the board of directors. The biotechnology company specializing in precision phage therapy intended to treat bacterial infections resistant to antibiotics and/or complicated, announces that Didier Hoch, previously Chairman and Chief Executive Officer, has been appointed Chairman of the Board of Directors.
A graduate of Essec, Thibaut du Fayet was previously vice-president of Transgene in charge of corporate development.
AOF – LEARN MORE
Find out more about the “pharmacy” sector
Loss of speed in European research
European research is losing ground to American and Chinese research. In twenty years, Europe’s share has fallen from 41% to 31% in global R&D. China’s share jumped from 1% to 8%. As for the United States, which supplanted Europe, in 2001 it devoted only 2 billion euros per year more than Europe to R&D, whereas now this gap has reached 25 billion! Some experts accuse the European authorities of not having deployed effective policies. The financing of pharmaceutical research should therefore have been better targeted via the “Horizon 2020” programme. France only comes in eighteenth position in European funding despite the quality of its research. Conversely, the United States concentrates funding on Boston and a few centers of excellence.